{
    "name": "pirfenidone",
    "comment": "Rx",
    "other_names": [
        "Esbriet"
    ],
    "classes": [
        "Transforming Growth Factor Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/esbriet-pirfenidone-999972",
    "pregnancy": {
        "common": [
            "Pregnancy: Data in pregnant women are insufficient to inform on drug associated risks for major birth defects and miscarriage",
            "Lactation: No information is available on presence of pirfenidone in human milk, effects of drug on breastfed infant, or effects of drug on milk production; lack of clinical data during lactation precludes clear determination of risk of pirfenidone to infant during lactation; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and potential adverse effects on breastfed child from pirfenidone or from underlying maternal condition"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: No information is available on presence of pirfenidone in human milk, effects of drug on breastfed infant, or effects of drug on milk production; lack of clinical data during lactation precludes clear determination of risk of pirfenidone to infant during lactation; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and potential adverse effects on breastfed child from pirfenidone or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Photosensitivity and rash reported; avoid or minimize exposure to sunlight (including sunlamps), to use a sunblock (SPF 50 or higher), and to wear clothing that protects against sun exposure; additionally, instruct patients to avoid concomitant medications known to cause photosensitivity; dosage reduction or discontinuation may be necessary in some cases of photosensitivity reaction or rash",
                "Nausea, vomiting, diarrhea, dyspepsia, gastroesophageal reflux disease, and abdominal pain reported; incidence of gastrointestinal events reported to be highest early in the course of treatment (with highest incidence occurring during initial 3 months); may decrease over time; temporary dosage reductions or discontinuations may be required"
            ],
            "specific": [
                {
                    "type": "Drug-induced liver injury",
                    "description": [
                        "Conduct liver function tests (ALT, AST, and bilirubin) before initiating, monthly for 6 months, and then q3months thereafter and, as clinically indicated",
                        "Patients treated with 2403 mg/day reported having higher incidence of elevated ALT/AST in clinical trials",
                        "Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice",
                        "Dosage modifications, interruption, or discontinuation may be necessary to reverse liver enzyme elevation"
                    ]
                },
                {
                    "type": "Cutaneous adverse reactions",
                    "description": [
                        "Severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), reported in association with therapy in the postmarketing setting",
                        "If signs or symptoms of SCAR occur, interrupt treatment until etiology of the reaction has been determined; consultation with a dermatologist recommended; if a SCAR is confirmed, permanently discontinue therapy"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Pirfenidone is a CYP1A2 substrate; discontinue moderate or strong CYP1A inhibitors before initiating pirfenidone and avoid use during therapy; if unable to avoid, pirfenidone dose reduction required",
                        "Discontinue strong CYP1A2 inducers before initiating pirfenidone and avoid use during therapy; likely to decrease exposure and lead to loss of pirfenidone efficacy",
                        "Smoking associated with decreased systemic exposure; encourage patient to quit smoking"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated.  Use of strong CYP1A2 inducers should be discontinued before initiating pirfenidone and avoided during treatment"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated.  Use of strong CYP1A2 inducers should be discontinued before initiating pirfenidone and avoided during treatment"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated.  Use of strong CYP1A2 inducers should be discontinued before initiating pirfenidone and avoided during treatment"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Contraindicated.  Use of strong CYP1A2 inducers should be discontinued before initiating pirfenidone and avoided during treatment"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid oral",
            "description": {
                "common": "aminolevulinic acid oral, pirfenidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid topical",
            "description": {
                "common": "pirfenidone, aminolevulinic acid topical.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cigarette smoking",
            "description": {
                "common": "cigarette smoking will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diclofenac",
            "description": {
                "common": "diclofenac will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating treatment and avoided during treatment; if strong CYP1A2 inhibitor is only option, dosage reduction recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "givosiran",
            "description": {
                "common": "givosiran will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration, decrease pirfenidone dose"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methoxsalen",
            "description": {
                "common": "methoxsalen will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methyl aminolevulinate",
            "description": {
                "common": "pirfenidone, methyl aminolevulinate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mexiletine",
            "description": {
                "common": "mexiletine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primaquine",
            "description": {
                "common": "primaquine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration of pirfenidone and moderate CYP1A2 inhibitors result in moderately increased exposure to pirfenidone; if unable to avoid, decrease dose of moderate CYP1A2 inhibitor"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zileuton",
            "description": {
                "common": "zileuton will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "cannabidiol, pirfenidone. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition  with the coadministration of CYP1A2  substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, pirfenidone. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "36"
        },
        {
            "name": "Rash",
            "percent": "30"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "27"
        },
        {
            "name": "Diarrhea",
            "percent": "26"
        },
        {
            "name": "Fatigue",
            "percent": "26"
        },
        {
            "name": "Abdominal pain",
            "percent": "24"
        },
        {
            "name": "Headache",
            "percent": "22"
        },
        {
            "name": "Decreased appetite",
            "percent": "21"
        },
        {
            "name": "Dyspepsia",
            "percent": "19"
        },
        {
            "name": "Dizziness",
            "percent": "18"
        },
        {
            "name": "Vomiting",
            "percent": "13"
        },
        {
            "name": "Gastroesophageal reflux disease",
            "percent": "11"
        },
        {
            "name": "GERD",
            "percent": "11"
        },
        {
            "name": "Sinusitis",
            "percent": "10"
        },
        {
            "name": "Insomnia",
            "percent": "10"
        },
        {
            "name": "Weight decreased",
            "percent": "10"
        },
        {
            "name": "Arthralgia",
            "percent": "9"
        },
        {
            "name": "Photosensitivity",
            "percent": "8"
        },
        {
            "name": "Decreased appetite",
            "percent": "8"
        },
        {
            "name": "Pruritus",
            "percent": "6"
        },
        {
            "name": "Asthenia",
            "percent": "6"
        },
        {
            "name": "Dysgeusia",
            "percent": "5"
        },
        {
            "name": "Noncardiac chest pain",
            "percent": "3"
        },
        {
            "name": "AST",
            "percent": "3.7"
        },
        {
            "name": "ALT",
            "percent": "10"
        },
        {
            "name": "x ULN",
            "percent": "0.3"
        },
        {
            "name": "AST",
            "percent": null
        },
        {
            "name": "ALT",
            "percent": null
        },
        {
            "name": "x ULN",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Drug",
            "percent": null
        },
        {
            "name": "induced liver injury",
            "percent": null
        },
        {
            "name": "Skin and Subcutaneous Tissue Disorders",
            "percent": null
        },
        {
            "name": "Severe Cutaneous Adverse Reactions",
            "percent": null
        },
        {
            "name": "SCAR",
            "percent": null
        }
    ]
}